Xeloda 150 mg film-coated tablets

Xeloda 150 mg film-coated tablets
Active substance(s)Capecitabine
Country of admissiongb
Marketing authorisation holderRoche Registration Ltd.
ATC CodeL01BC06
Pharmacological groupsAntimetabolites

Patient information leaflet

What is it and what is it used for?

Xeloda belongs to the group of medicines called "cytostatic agents", which stop the growth of cancer cells. Xeloda contains 150 mg capecitabine, which itself is not a cytostatic agent. Only after being absorbed by the body is it changed into an active anti-cancer agent (more in tumour tissue than in normal tissue).

Xeloda is prescribed by doctors for the treatment of colon, rectal, gastric, or breast cancers. Furthermore, Xeloda is prescribed by doctors to prevent new occurrence of colon cancer after complete removal of the tumour by surgery.

Xeloda may be used either alone or in combination with other agents.

What should you consider before use?

Do not take Xeloda:
  • if you are allergic (hypersensitive) to capecitabine or any of the other ingredients of Xeloda. You must inform your doctor if you know that you have an allergy or over-reaction to Xeloda,
  • if you are pregnant or nursing,
  • if you have blood disorders,
  • if you have liver ailments or kidney problems,
  • if you have a known deficiency for the enzyme dihydropyrimidine dehydrogenase (DPD), or
  • if you are being treated now or have been treated in the last 4 weeks with brivudine, sorivudine or similar classes of substance as part of herpes zoster (chickenpox or shingles) therapy.

Take special care with Xeloda:
Before treatment with Xeloda, make sure your doctor knows if you

  • have liver or kidney diseases
  • have or had other illnesses, such as heart problems or chest pain
  • have brain diseases
  • have calcium imbalances
  • have diabetes

Taking other medicines:

Before starting treatment, please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.This is extremely important, as taking more than one medicine at the same time can strengthen or weaken the effect of the medicines. You need to be particularly careful if you are taking any of the following:

  • gout medicines (allopurinol),
  • blood-thinning medicines (coumarin, warfarin),
  • certain anti-viral medicines (sorivudine and brivudine) or
  • medicines for seizures or tremors (phenytoin).

Taking Xeloda with food and drink:
You should take Xeloda no later than 30 minutes after meals.

Pregnancy and breast-feeding
Before starting treatment, you must tell your doctor if you are pregnant, if you think you are pregnant or if you intend to become pregnant. You should not take Xeloda if you are pregnant or think you might be. You should not breast-feed if you are taking Xeloda. Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines:
Xeloda may make you feel dizzy, nauseous or tired. It is therefore possible that Xeloda could affect your ability to drive a car or operate machinery.

Important information about some of the ingredients of Xeloda:

This medicinal product contains anhydrous lactose as an excipient. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Xeloda.

How is it used?

Xeloda tablets should be swallowed with water.

Your doctor will prescribe a dose and treatment regimen that is right for you. The dose of Xeloda is based on your body surface area. This is calculated from your height and weight. The usual dose for adults is 1250 mg/m 2 of body surface area taken two times daily (morning and evening). Two examples are provided here: A person whose body weight is 64 kg and height is 1.64 m has a body surface area of 1.7 m 2 and should take 4 tablets of 500 mg and 1 tablet of 150 mg two times daily. A person whose body weight is 80 kg and height is 1.80 m has a body surface area of 2.00 m 2 and should

Xeloda tablets are usually taken for 14 days followed by a 7 day rest period (when no tablets are taken). This 21 day period is one treatment cycle.

In combination with other agents the usual dose for adults may be less than 1250 mg/m 2 of body surface area, and you may need to take the tablets over a different time period (e.g. every day, with no rest period).

Your doctor will tell you what dose you need to take, when to take it and for how long you need to take it.

Your doctor may want you to take a combination of 150 mg and 500 mg tablets for each dose.

  • Take the tablets in the combination prescribed by your doctor for your morning and evening doses.
  • Take the tablets within 30 minutes after the end of a meal (breakfast and dinner).
  • It is important that you take all your medication as prescribed by your doctor.

If you take more Xeloda than you should, contact your doctor before taking the next dose.

If you forget to take Xeloda: do not take the missed dose at all and do not double the next one. Instead, continue your regular dosing schedule and check with your doctor.

If you stop taking Xeloda:
There are no side-effects caused by stopping treatment with Xeloda. In case you are using coumarin anticoagulants (e.g. Marcumar), stopping Xeloda might require that your doctor adjusts your anticoagulant dose.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

What are possible side effects?

Like all medicines, Xeloda can cause side effects, although not everybody gets them.

When Xeloda is used alone, the most common side effects which may affect more than 1 person in 10 are:

  • diarrhoea, nausea, vomiting, stomatitis (sores in mouth and throat) and abdominal pain
  • hand-and-foot skin-reaction (palms of the hands or soles of the feet tingle, become numb, painful, swollen or red), rash, dry or itchy skin
  • tiredness
  • loss of appetite (anorexia)

These side effects can become severe; therefore, it is important that you always contact your doctor immediately when you start to experience a side effect. Your doctor may instruct you to decrease the dose and/or temporarily discontinue treatment with Xeloda. This will help reduce the likelihood that the side effect continues or becomes severe.

STOP taking Xeloda immediately and contact your doctor if any of these symptoms occur:

  • Diarrhoea: if you have an increase of 4 or more bowelmovements compared to your normal bowel movements each day or any diarrhoea at night.
  • Vomiting: if you vomit more than once in a 24-hour time period.
  • Nausea: if you lose your appetite, and the amount of food you eat each day is much less than usual.
  • Stomatitis: if you have pain, redness, swelling or sores in your mouth.
  • Hand-and-foot skin-reaction: if you have pain, swelling, and redness of hands and/or feet
  • Fever or Infection: if you have a temperature of 38°C or greater, or other signs of infection.
  • Chest pain: if you experience pain localised to the centre of the chest, especially if it occurs during exercise .

If caught early, these side effects usually improve within 2 to 3 days after treatment discontinuation. If these side effects continue, however, contact your doctor immediately. Your doctor may instruct you to restart treatment at a lower dose.

Other less common and usually mild side-effects which may affect between 1 and 10 people in 100 have been seen: decreases in the number of white blood cells or red blood cells, skin rashes, slight hair loss, weariness, fever, weakness, drowsiness, headache, numbness or tingling sensations, taste changes, dizziness, sleeplessness, swelling in the legs, constipation, dehydration, cold sores, inflammation of the nose and throat, chest infection, depression, problems with the eyes, inflammation of the veins (thrombophlebitis), shortness of breath, nose bleeds, cough, runny nose, bleeding from the gut, heartburn, excess wind, dry mouth, skin discolouration, nail disorder, pain in the joints, chest or back and loss of weight.

If you are concerned about these or any other unexpected effect(s), talk to your doctor. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

How should it be stored?

Keep out of the reach and sight of children

Do not store above 30°C

Do not use Xeloda after the expiry date which is stated on the outer pack and label.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

Further information

What Xeloda contains
  • The active substance is capecitabine (150 mg per film-coated tablet).
  • The other ingredients are:
  • Tablet core: anhydrous lactose, croscarmellose sodium, hypromellose, microcrystalline cellulose, magnesium stearate.
  • Tablet coating: hypromellose, titanium dioxide (E171), yellow and red iron oxide (E172), talc.
What Xeloda looks like and contents of the pack

Light peach film-coated tablet of biconvex, oblong shape with the marking ?150? on the one side and ?Xeloda? on the other side.

Xeloda 150 mg film-coated tablet pack contains 60 film-coated tablets (6 blisters of 10 tablets).

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder:
Roche Registration Limited
6 Falcon Way
Shire Park
Welwyn Garden City
AL7 1TW
United Kingdom

Manufacturer:
Roche Pharma AG
Emil-Barell-Str. 1
D-79639 Grenzach-Wyhlen
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.

LuxembourgLuxemburg Voirsiehe BelgiqueBelgien BelgiëBelgiqueBelgien N.V. Roche S.A. TélTel 32 0 2 525 82 11

359 2 818 44 44 Magyarország Roche Magyarország Kft. Tel 36 - 23 446 800

Malta See United Kingdom eská republika Roche s. r. o. Tel 420 - 2 20382111 Danmark Roche as Tlf 45 - 36 39 99 99 Nederland Roche Nederland B.V. Tel 31 0 348 438050

Deutschland Roche Pharma AG Tel 49 0 7624 140 Norge Roche Norge AS Tlf 47 - 22 78 90 00

Eesti Roche Eesti OÜ Tel 372 - 6 177 380 Österreich Roche Austria GmbH Tel 43 0 1 27739

Roche Hellas A.E. 30 210 61 66 100 Polska Roche Polska Sp.z o.o. Tel 48 - 22 345 18 88

España Roche Farma S.A. Tel 34 - 91 324 81 00 Portugal Roche Farmacêutica Química, Lda Tel 351 - 21 425 70 00

France Roche Tél 33 0 1 46 40 50 00 România Roche România S.R.L. Tel 40 21 206 47 01

Ireland Roche Products Ireland Ltd. Tel 353 0 1 469 0700 Slovenija Roche farmacevtska druba d.o.o. Tel 386 - 1 360 26 00

Slovenská republika Roche Slovensko, s.r.o. Tel 421 - 2 52638201 Ísland Roche as co Icepharma hf Simi 354 540 8000

Italia Roche S.p.A. Tel 39 - 039 2471 SuomiFinland Roche Oy PuhTel 358 0 10 554 500

K .. . 357 - 22 76 62 76 Sverige Roche AB Tel 46 0 8 726 1200

Latvija Roche Latvija SIA Tel 371 - 6 7 039831 United Kingdom Roche Products Ltd. Tel 44 0 1707 366000

Lietuva

UAB ?Roche Lietuva?
Tel: +370 5 2546799

This leaflet was last approved in {MM/YYYY}

Last updated on 24.08.2023

More drugs with the same active ingredient

The following drugs also contain the active ingredient Capecitabine. Consult your doctor about a possible substitute for Xeloda 150 mg film-coated tablets

Drug
Marketing authorisation holder

Logo

Your personal medication assistant

Drugs

Browse our extensive database of medications from A-Z, including effects, side effects, and dosage.

Substances

All active ingredients with their effects, applications, and side effects, as well as the medications they are contained in.

Diseases

Symptoms, causes, and treatments for common diseases and injuries.

Social media

The presented content does not replace the original package insert of the medication, especially regarding the dosage and effects of individual products. We cannot assume liability for the accuracy of the data, as the data has been partially converted automatically. Always consult a doctor for diagnoses and other health-related questions.

© medikamio